Last reviewed · How we verify
NCT04337996: TRODVID-19
Dynamic Evaluation of COVID-19 Diagnostic Tests
NA trial testing COVID-19 diagnostic test in COVID-19 in 8 participants. Completed in 13 January 2021.
13 January 2021
Quick facts
| Lead sponsor | Tourcoing Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 8 |
| Start date | 13 July 2020 |
| Primary completion | 13 January 2021 |
| Estimated completion | 13 January 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- COVID-19 diagnostic test
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Tourcoing Hospital
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rapid antigenic tests are not yet used in real life. Their contribution in the diagnostic strategy based on the gold standard including anamnesis, thoracic CT and PCR has not been evaluated. We propose to compare to the Gold-Standard defined above, the combination of an SARS-Cov-2 antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04337996
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Tourcoing Hospital trials
Trials by the same sponsor.
- NCT06441383 — Assessment of Sleep Disordersin People Living With HIV in the Era of New Antiretroviral Therapies in North of France · not yet recruiting
- NCT06441370 — Patient Satisfaction During Physiological Water or Land Birth: a Prospective Study in an French Tertiary Maternity Unit. · recruiting
- NCT05833282 — Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU · unknown
- NCT04429724 — Health Professional Exposure Assessment to Covid-19 · NA · completed
- NCT04402684 — Influenza Vaccination in Patients Living With HIV in the Northern Region · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04337996 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tourcoing Hospital
- Last refreshed: 26 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04337996.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing